BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 27, 2026
Home » Topics » Immune, BioWorld Science

Immune, BioWorld Science
Immune, BioWorld Science RSS Feed RSS

Ocular

New mouse model of Sjögren’s disease-associated dry eye

Feb. 23, 2026
No Comments
Scientists based at Capital Medical University (Beijing, China) have designed a lacrimal gland-specific autoimmune model that recapitulates the main features of Sjögren’s disease-associated dry eye.
Read More
X-ray image of hand and wrist
Immune

T cells store lipids and die in rheumatoid arthritis joints

Feb. 18, 2026
By Mar de Miguel
No Comments
In the inflamed joints of rheumatoid arthritis, CD4+ T lymphocytes accumulate lipid droplets that make them vulnerable and promote their death, thereby amplifying joint inflammation. A study led by scientists at Mayo Clinic and Stanford University suggests that blocking the formation of these lipid droplets or their contents could offer a therapeutic strategy for this condition.
Read More
Colorized scanning electron microscope image of regulatory T cells and antigen-presenting cells.
Immune

Cue’s CUE-401 well tolerated in mouse and NHP studies

Feb. 18, 2026
No Comments
Cue Biopharma Inc. has reported preclinical safety and tolerability data on CUE-401, the company’s lead asset for autoimmune and inflammatory diseases. CUE-401 is designed to act mechanistically both as a regulator of pro-inflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance.
Read More
Scientists shaking hands in the lab
Immune

Asahi Kasei Pharma acquires rights to Alchemedicine compounds

Feb. 17, 2026
No Comments
Alchemedicine Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement on lead HiSAP (high solubility and permeability) compounds owned by Alchemedicine.
Read More
Colorized scanning electron micrograph of a T lymphocyte.
Immuno-oncology

SLAMF6 is suppressor of T-cell cancer immunity

Feb. 16, 2026
By Mar de Miguel
No Comments
SLAMF6 is an immune cell receptor whose function was not clear. Does it activate or inhibit cells? The results so far have been contradictory. Now, scientists at the Institut de Recherches Cliniques de Montréal (IRCM) have unveiled evidence that SLAMF6, a protein of the SLAM family that binds to copies of itself, is regulated by interactions between molecules of the same receptor within the same cell.
Read More
Interleukin 17 (IL-17)
Immune

Quantx raises $85M to advance oral immunology drugs

Feb. 13, 2026
By Tamra Sami
No Comments
After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor.
Read More
Immune

Ewha Womans University identifies new BTK inhibitors

Feb. 13, 2026
Ewha Womans University has reported Bruton tyrosine kinase (BTK) inhibitors described as potentially useful for the treatment of autoimmune disease and cancer.
Read More
Illustration of DNA-based vaccine for HIV
HIV/AIDS

DNA origami vaccine produces broadly neutralizing HIV antibodies

Feb. 13, 2026
By Mar de Miguel
No Comments
The use of DNA scaffolds could mark a turning point in HIV vaccine design. Scientists at Scripps Research and the Massachusetts Institute of Technology (MIT) have created a new vaccine platform based on DNA origami, a material that the immune system does not recognize as a threat, avoiding unwanted responses.
Read More
Illustration of normal muscle compared to muscle atrophy in cancer cachexia or anorexia
Cancer

Tumor, immune and neural cells are involved in cancer cachexia

Feb. 12, 2026
By Mar de Miguel
No Comments
A circuit formed by tumor, immune and nervous systems triggers cancer cachexia and anorexia, the excessive loss of weight, muscle and fat experienced in some cancer types. A new study is the first showing these three actors of a triangle interaction that initiates and feeds the process.
Read More
Park Tae-yong, vice president and cofounder, Galux
Drug design, drug delivery & technologies

AI meets antibody design: Galux draws $29M series B for drug R&D

Feb. 10, 2026
By Marian (YoonJee) Chu
No Comments
Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 574 575 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • Chengdu Mfs Pharma synthesizes new compounds for pain

    BioWorld Science
    Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing